Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Tagshop AI Levels Up Video Creation With Kling 4.0Tagshop AI, an AI-powered content creation platform built to help brands produce engaging visual content, has expanded its video generation capabilities with the addition of Kling 4.0.
- OpenAISullivan & Cromwell brings legal expertise into agreement reviewCompanies: OpenAIIn collaboration with OpenAI, Sullivan & Cromwell developed Agreement Analyzer, an AI tool for identifying issues in a draft agreement.
- XPENGXPENG CEO He Xiaopeng Calls for Deeper Global Collaboration at the 2026 Paris Automotive Summit, Highlighting "XPENG AI Engineering"Mr. He Xiaopeng, Chairman & CEO, becomes the first Chinese automotive CEO to deliver a keynote in the history of the Paris Automotive Summit, calling for greater industry collaboration as AI, electrification and globalization reshapes the automotive sector. Mr. He Xiaopeng introduced...
- IBMIBM Study: Eight in Ten EMEA Enterprises Escalate AI Incidents to Board or C-Suite as AI Agents Test GovernanceCompanies: IBM80% of surveyed executives in EMEA say an AI-related incident reached their board or C-suite in the past year, with only 40% changing AI governance policy or frameworks in response. 75% of respondents expect AI agents to have some level of autonomy with respect to decisions by 2027, yet...
- IBMIBM Study: Eight in Ten EMEA Enterprises Escalate AI Incidents to Board or C-Suite as AI Agents Test GovernanceCompanies: IBM• 80% of surveyed executives in EMEA say an AI-related incident reached their board or C-suite in the past year, with only 40% changing AI governance policy or frameworks in response.
- TuneAIBot Invites US Tour Operators to Evaluate AI-Powered Guest Support Leveraging Their Own WebsitesRabby's USA, Inc., the U.S. sales company for TuneAIBot, today invited U.S. tour operators to explore a 30-day evaluation of TuneAIBot, an AI customer-support platform developed by Japan-based Surge Craft Co., Ltd.
- KUKUI Appoints Heather Myers CEO to Lead Next Era of AI-Powered InnovationLAS VEGAS, Nev. — October 14, 2026 — KUKUI Holdings, Inc., a leading provider of marketing and customer engagement technology built specifically for the automotive repair industry, today announced that Heather Myers has assumed the role of Chief Executive Officer, effective October 1, 2026. Myers succeeds Eric Harber, who stepped down after more than […]
- LabelboxLabelbox raises $100 Million+ in Series E funding to advance reinforcement learning and enterprise AI agentsFunding will accelerate development of Horizon, which helps frontier AI labs train and evaluate models, and Recursion Managed Agents, which enables enterprises to deploy agents that improve through experience. SAN FRANCISCO, Oct. 14, 2026 -- Labelbox, the AI platform powering...
- Colossal Biosciences Inc.Colossal Accelerates the Full Dodo De-extinction PipelineNew AI platform GenoMorph identifies candidate regulatory DNA linked to the dodo's distinctive craniofacial anatomy, while technologies adapted from earlier species programs advance Nicobar pigeon germ-cell development, chicken stem-cell chimeras and embryo gene editing. DALLAS, Oct. 14,...
- TrueLoyalTrueLoyal Puts Loyalty Program Data Inside Any AI Assistant, So Teams Can Get Answers Without Waiting on a ReportThe TrueLoyal MCP, now in beta, lets loyalty teams ask questions about their members and purchases in plain language and build their own dashboards. — TrueLoyal, the loyalty and advocacy platform behind Rewards and Fan Club™, today announced that...
- SamsungSamsung Expands Language Support Across AI Experiences on GalaxyCompanies: Samsung ElectronicsSamsung is expanding language support for Galaxy AI and Bixby, bringing these experiences to more users in their own language. Galaxy AI is expanding language support across more of its features, starting with those that translate, transcribe, and summarize. Call Assist, Note Assist, Interpreter, and Transcript Assist now include Hungarian and Malay, bringing features such […]
- MindMaze Therapeutics Reports New Home-Based Rehabilitation Results Ahead of MindMotion Lite LaunchMulti-site Program Demonstrates Threefold Increase in Rehabilitation Training Dose, With 84% Delivered Independently and Significant Improvements Across Functional Measures GENEVA, SWITZERLAND - October 14, 2026 - MindMaze Therapeutics (SIX: MMTX), a global leader in scalable precision neurotherapeutics, today announced new real-world evidence from a multi-site program conducted with Vibra Healthcare, presented yesterday at the American Congress of Rehabilitation Medicine (ACRM) in Washington, DC. The program demonstrated that home-based rehabilitation using MindMotion increased total motor-training dose by a median factor of three compared with usual outpatient therapy alone. 84% of active training was completed independently, without direct therapist supervision. Participants also showed statistically significant improvements in functional independence, balance, mobility and cognition, alongside high patient satisfaction. Building on previously reported inpatient results with Vibra Healthcare, the findings further support MindMaze Therapeutics' strategy to extend high-dose, high-intensity neurorehabilitation into patients' homes. This is particularly relevant to the Company's upcoming launch of MindMotion Lite, expected by year-end 2026. Recently announced, the tablet-based solution is designed to deliver the full range of MindMotion GO neurotherapeutic activities with substantially reduced hardware requirements, simplifying home deployment and supporting broader adoption by healthcare providers. “Earlier this year, we showed that MindMaze's high-dose, high-intensity therapy, integrated into inpatient rehabilitation, delivers superior functional outcomes in a resource-efficient way,” said Zach Henderson, CEO of MindMaze Therapeutics. “Now, we are demonstrating that this value can extend into the home to address a well-recognized gap in care once patients leave the clinic, in line with the 2026 AHA/ASA Guideline for Adult Stroke Rehabilitation and Recovery. These results, combined with our upcoming MindMotion Lite tablet-based solution, will help make high-quality neurotherapeutics more accessible. Together, these milestones bring us closer to our mission of making neurotherapeutics available at scale.” Study Design and Results The retrospective, multi-site quality improvement program evaluated 177 rehabilitation episodes involving 172 adults with a range of neurological conditions, primarily stroke, across four Vibra Healthcare outpatient sites, without a control group. Participants followed an eight-week home-training program using MindMotion GO, with an optional four-week extension and periodic therapist supervision. Key findings included: Training dose: Patients completed an average of 174 minutes of active training per week, with 84.4% delivered asynchronously. The additional home training increased total motor-training dose by a median factor of 3.0 compared with usual outpatient therapy alone, based on published assumptions for active practice during usual care. Feasibility and engagement: 92.7% successfully completed home setup, while 80.2% achieved the predefined minimum training exposure. Among surveyed participants, 83.8% of satisfaction ratings were positive. Functional outcomes: Statistically significant pre–post improvements were observed in independence (Barthel Index: +10.4 points), balance (Berg Balance Scale: +10.5 points), cognition (SLUMS: +3.4 points) and mobility (Timed Up and Go: −8.8 seconds) among participants with available paired assessments. The full poster, High-Dose, Home-Based Neurorehabilitation Using Gamified Technology: A Multi-Site Quality Improvement Program, is available at mindmazetherapeutics.com/mindmaze-platform/clinical-evidence. About MindMaze Therapeutics MindMaze Therapeutics (SIX: MMTX) is a global leader in scalable, precision neurotherapeutics, dedicated to redefining the recovery trajectory for patients around the world. By integrating advanced software, proprietary sensors, and AI-driven data analytics, MindMaze Therapeutics provides a seamless continuum of care from the acute hospital phase to outpatient treatment to home-based therapy. The company's FDA-listed and CE-marked products are designed to address the systemic shortage of specialized clinicians, offering scalable, reimbursable solutions for stroke, Parkinson's disease, and other neurological disorders. With an extensive library of rigorous clinical validation, MindMaze Therapeutics is operationalizing the future of neurorestorative medicine. For more information, visit www.mindmazetherapeutics.com. Media & Investor Contacts Jeremy Meinen, Chief Financial Officer [email protected] DISCLAIMER This press release contains forward-looking statements, which may be identified by words such as "believe," "assume," "expect," "intend," "may," "could," "will," or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied. This communication is provided as of the date hereof, and MindMaze Therapeutics undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise. Additional features: File: Press release_MindMaze_Home-Based Rehabilitation Results